Zosano Pharma Corp (ZSAN) gains 4.39% for July 21

Equities Staff  |

Zosano Pharma Corp (NASDAQ: ZSAN) shares gained 4.39%, or $0.034 per share, to close Wednesday at $0.81. After opening the day at $0.79, shares of Zosano Pharma fluctuated between $0.82 and $0.79. 1,001,749 shares traded hands a decrease from their 30 day average of 1,238,503. Wednesday's activity brought Zosano Pharma’s market cap to $86,343,252.

Zosano Pharma is headquartered in Fremont, California..

About Zosano Pharma Corp

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.

Visit Zosano Pharma Corp’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Zosano Pharma Corp and to follow the company’s latest updates, you can visit the company’s profile page here: Zosano Pharma Corp’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content